phosphorylcholine has been researched along with Cancer of Lung in 31 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 9.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| "To assess the response rate and toxicity of the alkylphosphocholine analogue, perifosine, in patients with metastatic or recurrent malignant melanoma." | 5.11 | Phase II study of perifosine in previously untreated patients with metastatic melanoma. ( Baetz, T; Belanger, K; Davis, M; Eisenhauer, E; Ernst, DS; Lohmann, R; Smylie, M; Wainman, N, 2005) |
| " Previously, we showed that dual liposomes simultaneously containing the hemostatic inhibitor, dipyridamole and the anticancer drug, perifosine potently inhibited metastasis, causing a 90% reduction in the number of lung metastases in a murine experimental metastasis model." | 3.76 | Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation. ( Fichtner, I; Habedank, S; Haider, W; Wenzel, J; Zeisig, R, 2010) |
| " In addition, at the highest dosage group in rats, an increase in white blood cell counts (WBC) was observed." | 2.67 | Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine. ( Drogendijk, TE; Oosterom, R; Planting, AS; Pronk, LC; Stoter, G; Verweij, J, 1994) |
| " In vivo, we further revealed that the chronic administration of low-doses of paclitaxel - i." | 1.46 | Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression. ( André, N; Berges, R; Borge, L; Bourgarel, V; Braguer, D; Buric, D; Carré, M; Carrier, A; Le Grand, M; Montero, MP; Pasquier, E; Vasseur, S, 2017) |
| "Lung cancer is a global health problem." | 1.42 | Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo. ( Hong, Y; Shen, J; Zhang, J, 2015) |
| "Formation of lung and extrapulmonary metastases after intravenous administration of MT3 breast cancer cells was significantly reduced when mice were treated with a single intravenous dose of DIP/OPP-L containing 100nmol lipid 6h before tumour cell inoculation." | 1.35 | Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation. ( Fichtner, I; Wenzel, J; Zeisig, R, 2009) |
| "Perifosine is an orally bioavailable alkylphospholipid currently being tested in phase II clinical trials as a potential anticancer drug." | 1.35 | Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism. ( Elrod, HA; Khuri, FR; Sun, SY; Yue, P, 2009) |
| "Perifosine is an alkylphospholipid exhibiting antitumor activity as shown in both preclinical studies and clinical trials." | 1.35 | Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy. ( Fu, L; Khuri, FR; Kim, YA; Lonial, S; Sun, SY; Wang, X; Wu, X; Yue, P, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.23) | 18.7374 |
| 1990's | 7 (22.58) | 18.2507 |
| 2000's | 9 (29.03) | 29.6817 |
| 2010's | 11 (35.48) | 24.3611 |
| 2020's | 3 (9.68) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, CY | 1 |
| Yang, JL | 1 |
| Chen, JJ | 1 |
| Tai, SB | 1 |
| Yeh, YH | 1 |
| Liu, PF | 1 |
| Lin, MW | 1 |
| Chung, CL | 1 |
| Chen, CL | 1 |
| Wang, P | 1 |
| Yuan, Y | 1 |
| Qiu, M | 1 |
| Yamaguchi, T | 1 |
| Yoshimura, T | 1 |
| Ohara, T | 1 |
| Fujisawa, M | 1 |
| Tong, G | 1 |
| Matsukawa, A | 1 |
| Le Grand, M | 1 |
| Berges, R | 1 |
| Pasquier, E | 1 |
| Montero, MP | 1 |
| Borge, L | 1 |
| Carrier, A | 1 |
| Vasseur, S | 1 |
| Bourgarel, V | 1 |
| Buric, D | 1 |
| André, N | 1 |
| Braguer, D | 1 |
| Carré, M | 1 |
| Wu, DW | 1 |
| Lee, MC | 1 |
| Hsu, NY | 1 |
| Wu, TC | 1 |
| Wu, JY | 1 |
| Wang, YC | 1 |
| Cheng, YW | 1 |
| Chen, CY | 1 |
| Lee, H | 1 |
| Yue, H | 1 |
| Li, W | 1 |
| Liu, P | 1 |
| Gao, J | 1 |
| Miao, J | 1 |
| Zhao, J | 1 |
| Zhang, J | 1 |
| Hong, Y | 1 |
| Shen, J | 2 |
| Lee, EJ | 1 |
| Park, MK | 2 |
| Kim, HJ | 2 |
| Kim, EJ | 2 |
| Kang, GJ | 2 |
| Byun, HJ | 2 |
| Lee, CH | 2 |
| Xu, L | 1 |
| Zhao, Q | 1 |
| Srinual, S | 1 |
| Chanvorachote, P | 1 |
| Pongrakhananon, V | 1 |
| Wenzel, J | 2 |
| Zeisig, R | 3 |
| Fichtner, I | 3 |
| Haider, W | 1 |
| Habedank, S | 1 |
| Elrod, HA | 2 |
| Yue, P | 3 |
| Khuri, FR | 3 |
| Sun, SY | 3 |
| Fu, L | 1 |
| Kim, YA | 1 |
| Wang, X | 3 |
| Wu, X | 1 |
| Lonial, S | 2 |
| Gills, JJ | 1 |
| Zhang, C | 1 |
| Abu-Asab, MS | 1 |
| Castillo, SS | 1 |
| Marceau, C | 1 |
| LoPiccolo, J | 1 |
| Kozikowski, AP | 1 |
| Tsokos, M | 1 |
| Goldkorn, T | 1 |
| Dennis, PA | 1 |
| Ma, Z | 1 |
| Zhu, L | 1 |
| Luo, X | 1 |
| Zhai, S | 1 |
| Li, P | 1 |
| Dasmahapatra, GP | 1 |
| Didolkar, P | 1 |
| Alley, MC | 1 |
| Ghosh, S | 1 |
| Sausville, EA | 1 |
| Roy, KK | 1 |
| Ernst, DS | 1 |
| Eisenhauer, E | 1 |
| Wainman, N | 1 |
| Davis, M | 1 |
| Lohmann, R | 1 |
| Baetz, T | 1 |
| Belanger, K | 1 |
| Smylie, M | 1 |
| Pinchuk, AN | 1 |
| Rampy, MA | 1 |
| Longino, MA | 1 |
| Skinner, RW | 1 |
| Gross, MD | 1 |
| Weichert, JP | 1 |
| Counsell, RE | 1 |
| Lin, YD | 1 |
| Glunde, K | 1 |
| Bhujwalla, ZM | 2 |
| Pronk, LC | 1 |
| Planting, AS | 1 |
| Oosterom, R | 1 |
| Drogendijk, TE | 1 |
| Stoter, G | 2 |
| Verweij, J | 2 |
| Theischen, M | 1 |
| Bornfeld, N | 1 |
| Becher, R | 1 |
| Kellner, U | 1 |
| Wessing, A | 1 |
| Nakai, T | 1 |
| Ishima, R | 1 |
| Sakahara, H | 1 |
| Endo, K | 1 |
| Konishi, J | 1 |
| Akasaka, K | 1 |
| Manuel, SM | 1 |
| Guo, Y | 1 |
| Matalon, S | 1 |
| Aboagye, EO | 1 |
| Gillies, RJ | 1 |
| Chacko, VP | 1 |
| Mendola, CE | 1 |
| Backer, JM | 1 |
| Stahn, R | 1 |
| Planting, A | 1 |
| van der Burg, M | 1 |
| Bishop, FE | 1 |
| Dive, C | 1 |
| Freeman, S | 1 |
| Gescher, A | 1 |
| Onodera, K | 1 |
| Okubo, A | 1 |
| Yasumoto, K | 1 |
| Suzuki, T | 1 |
| Kimura, G | 1 |
| Nomoto, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Study Of Perifosine (D-21266) In Previously Untreated Patients With Metastatic Or Recurrent Malignant Melanoma[NCT00053781] | Phase 2 | 18 participants (Actual) | Interventional | 2003-06-20 | Completed | ||
| Phase 3 Open-label Study of Efficacy and Safety of Miltefosine or Thermotherapy vs Glucantime for Cutaneous Leishmaniasis in Colombia.[NCT00471705] | Phase 3 | 437 participants (Actual) | Interventional | 2006-06-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Complete Clinical response: Initial cure plus the absence of recurrences or mucosal lesions for 6 months after the end of treatment.~Note: nitial cure: Complete re-epithelialization of all ulcers and complete disappearance of the induration up to 3 months after the end of treatment." (NCT00471705)
Timeframe: Until 6 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 85 |
| Glucantime® | 103 |
| Thermotherapy | 86 |
At least 50% increase in lesion size at the end of treatment, absence of clinical response at 6 weeks, or any sign of lesion activity 3 months after the end of treatment (NCT00471705)
Timeframe: Until 3 months posttreatment
| Intervention | participants (Number) |
|---|---|
| Miltefosine | 34 |
| Glucantime® | 14 |
| Thermotherapy | 42 |
Reactivation of the lesion at the original site after cure or mucosal compromise during follow-up. (NCT00471705)
Timeframe: Until 6 months post-treatment
| Intervention | Participants (Number) |
|---|---|
| Miltefosine | 3 |
| Glucantime® | 4 |
| Thermotherapy | 6 |
4 trials available for phosphorylcholine and Cancer of Lung
| Article | Year |
|---|---|
Phase II study of perifosine in previously untreated patients with metastatic melanoma.
Topics: Adult; Aged; Aged, 80 and over; Arthralgia; Chondrocalcinosis; Female; Humans; Liver Neoplasms; Lung | 2005 |
Increases in leucocyte and platelet counts induced by the alkyl phospholipid hexadecylphosphocholine.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, | 1994 |
Hexadecylphosphocholine may produce reversible functional defects of the retinal pigment epithelium.
Topics: Adenocarcinoma; Antineoplastic Agents; Colorectal Neoplasms; Electrooculography; Electroretinography | 1993 |
A dose-finding study of miltefosine (hexadecylphosphocholine) in patients with metastatic solid tumours.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Colore | 1992 |
27 other studies available for phosphorylcholine and Cancer of Lung
| Article | Year |
|---|---|
Fluoroquinolones Suppress TGF-β and PMA-Induced MMP-9 Production in Cancer Cells: Implications in Repurposing Quinolone Antibiotics for Cancer Treatment.
Topics: A549 Cells; Anti-Bacterial Agents; Cell Line, Tumor; Cell Movement; Down-Regulation; Drug Reposition | 2021 |
Identification of Plasma Metabolites Associated with Lung Cancer Survival.
Topics: Humans; Lung Neoplasms; Mass Spectrometry; Metabolomics; Phosphorylcholine; Xanthine | 2023 |
PolyI:C suppresses TGF-β1-induced Akt phosphorylation and reduces the motility of A549 lung carcinoma cells.
Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Cell Movement; Epithelial-Mesenchymal Transition; H | 2021 |
Akt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.
Topics: Animals; Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; Cell Culture Techniques; | 2017 |
FHIT loss confers cisplatin resistance in lung cancer via the AKT/NF-κB/Slug-mediated PUMA reduction.
Topics: Acid Anhydride Hydrolases; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Apoptosis | 2015 |
Inhibition of autophagy promoted sphingosylphosphorylcholine induced cell death in non-small cell lung cancer cells.
Topics: Apoptosis; Autophagy; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Humans; Lung Neoplasms; Phos | 2014 |
Combination treatment with perifosine and MEK-162 demonstrates synergism against lung cancer cells in vitro and in vivo.
Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Combined Modality Therapy; Drug Synergism; | 2015 |
Epithelial membrane protein 2 regulates sphingosylphosphorylcholine-induced keratin 8 phosphorylation and reorganization: Changes of PP2A expression by interaction with alpha4 and caveolin-1 in lung cancer cells.
Topics: Adaptor Proteins, Signal Transducing; Blotting, Western; Caveolin 1; Cell Line, Tumor; Cell Movement | 2016 |
Perifosine and ABT-737 synergistically inhibit lung cancer cells in vitro and in vivo.
Topics: A549 Cells; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosi | 2016 |
Novel involvement of RhebL1 in sphingosylphosphorylcholine-induced keratin phosphorylation and reorganization: Binding to and activation of AKT1.
Topics: Apoptosis; Biomarkers, Tumor; Cell Proliferation; Gene Expression Regulation, Neoplastic; GTP-Bindin | 2017 |
Suppression of cancer stem-like phenotypes in NCI-H460 lung cancer cells by vanillin through an Akt-dependent pathway.
Topics: AC133 Antigen; Aldehyde Dehydrogenase; Aldehyde Dehydrogenase 1 Family; Benzaldehydes; Carcinoma, No | 2017 |
Inhibition of breast cancer metastasis by dual liposomes to disturb complex formation.
Topics: Animals; Antineoplastic Agents; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Dipyridamole; D | 2009 |
Inhibition of pulmonary metastasis in a human MT3 breast cancer xenograft model by dual liposomes preventing intravasal fibrin clot formation.
Topics: Animals; Antineoplastic Agents; Blood Coagulation; Blood Vessels; Cell Line, Tumor; Dipyridamole; Fe | 2010 |
Celecoxib antagonizes perifosine's anticancer activity involving a cyclooxygenase-2-dependent mechanism.
Topics: Antineoplastic Agents; Base Sequence; Blotting, Western; Carcinoma, Non-Small-Cell Lung; Celecoxib; | 2009 |
Perifosine inhibits mammalian target of rapamycin signaling through facilitating degradation of major components in the mTOR axis and induces autophagy.
Topics: Animals; Autophagy; Cell Cycle Proteins; Cell Line, Tumor; Chloroquine; F-Box Proteins; F-Box-WD Rep | 2009 |
Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Ceramides; ErbB Receptors; Female; Huma | 2012 |
Perifosine enhances mTORC1-targeted cancer therapy by activation of GSK3β in NSCLC cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Gene Knockdown Techniques; Glycog | 2012 |
In vitro combination treatment with perifosine and UCN-01 demonstrates synergism against prostate (PC-3) and lung (A549) epithelial adenocarcinoma cell lines.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protoco | 2004 |
Synthesis and structure-activity relationship effects on the tumor avidity of radioiodinated phospholipid ether analogues.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Female; Humans; Iodine Radioisotopes; Kid | 2006 |
The alkylphospholipid perifosine induces apoptosis of human lung cancer cells requiring inhibition of Akt and activation of the extrinsic apoptotic pathway.
Topics: Antineoplastic Agents; Apoptosis; Carcinoma, Non-Small-Cell Lung; CASP8 and FADD-Like Apoptosis Regu | 2007 |
Choline kinase alpha in cancer prognosis and treatment.
Topics: Carcinoma, Non-Small-Cell Lung; Choline; Choline Kinase; Humans; Lung Neoplasms; Magnetic Resonance | 2007 |
1H-magnetic resonance spectroscopic observation of cultured malignant cells pharmacologically induced to different phenotypes.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Butyrates; Butyric Acid; Cho | 1996 |
Exosurf enhances adenovirus-mediated gene transfer to alveolar type II cells.
Topics: Adenocarcinoma; Adenoviridae; Animals; Cells, Cultured; Drug Combinations; Epithelial Cells; Fatty A | 1997 |
Nm23-transfected MDA-MB-435 human breast carcinoma cells form tumors with altered phospholipid metabolism and pH: a 31P nuclear magnetic resonance study in vivo and in vitro.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinoma; Ethanolamines; Female; Genetic Vectors; Gly | 1999 |
Inhibition of carbohydrate mediated cell adhesion by liposomes as a possible [correction of possibile] way to prevent tumour metastasis.
Topics: Animals; Carbohydrate Metabolism; Carcinoma, Lewis Lung; Cell Adhesion; Cells, Cultured; CHO Cells; | 2002 |
Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Cell Membrane; Cell Survival; Dose-Response Relation | 1992 |
31P nuclear magnetic resonance analysis of lung cancer: the perchloric acid extract spectrum.
Topics: Adenoviridae; Aged; Antibodies, Monoclonal; Cell Line; Cell Transformation, Neoplastic; Choline; Fem | 1986 |